Y-mAbs Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview

Y-mAbs Therapeutics

09/05/2025 15:55

Y-mAbs Therapeutics Inc YMAB.OQ YMAB.O is expected to show a fall in quarterly revenue when it reports  results on May 13 for the period ending March 31 2025

The Princeton New Jersey-based  company is expected to report a 1.6% decrease in revenue to $19.605 million from $19.93 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.The company's guidance on March 4 2025, for the period ended March 31, was for revenue between $18.00 million and $21.00 million.

‚ÄčLSEG's mean analyst estimate for Y-mAbs Therapeutics Inc is for a loss of 21 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and 2 "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 4.2% in the last three months. ‚Äč

Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $18.00‚Äč, above‚Äč its last closing price of $4.04. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.11
-0.12
-0.15
Missed
-21.2
Sep. 30 2024
-0.16
-0.16
-0.16
Met
-1.6
Jun. 30 2024
-0.13
-0.13
-0.21
Missed
-59.8‚Äč
Mar. 31 2024
-0.14
-0.14
-0.15
Missed
-10.5
‚Äč‚ÄčDec. 31 2023
-0.20
-0.20
-0.02
Beat
90.1
Sep. 30 2023
-0.18
-0.19
-0.18
Beat
3.7‚Äč
Jun. 30 2023
-0.24
-0.24
-0.14
Beat
42.1
Mar. 31 2023
-0.32
-0.32
-0.15
Beat
52.9

This summary was machine generated May 9 at 14:55 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)